Actively Recruiting
A Cross-sectional Study Examining Fat Tissue Changes in Adults with Obstructive Sleep Apnea
Led by Mayo Clinic · Updated on 2026-02-13
120
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
M
Mayo Clinic
Lead Sponsor
N
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating how obstructive sleep apnea (OSA) affects fat tissue and its role in increasing the risk of cardiovascular disease. This study focuses on examining the cellular and molecular changes in fat tissue of adults with OSA compared to healthy individuals. It aims to better understand how damaged fat tissue may contribute to insulin resistance, inflammation, and higher blood pressure in people with OSA. The study involves comparing fat tissue samples from two groups: those with obstructive sleep apnea (defined by an Apnea Hypopnea Index of 5 or higher) and those without it (AHI less than 5). Researchers will analyze markers of cellular damage in the fat tissue, such as p16 and gamma H2AX, to identify differences. The study is observational and does not involve treatment, focusing on tissue analysis and cardiovascular health markers. Participants will undergo assessments including fat tissue sampling to measure cellular damage markers, body composition analysis, blood pressure monitoring over 24 hours, evaluation of vascular function, and insulin sensitivity tests. The primary outcome is the prevalence of specific damaged cells in fat tissue. The total study duration and visits are arranged to gather this data, with no investigational treatments administered. The study is sponsored by the Mayo Clinic and includes adults aged 18 to 60 years.
CONDITIONS
Brief Title
A Cross-sectional Study Examining Adipose Tissue in Obstructive Sleep Apnea
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 60 years
- Body mass index (BMI) of 40 kg/m2 or less
- Not currently smoking or using tobacco
- Individuals with treated hypertension, prehypertension, or dyslipidemia may participate
- Taking no prescription medications except those for asthma, allergies, depression, acid reflux, topical skin treatments, or birth control
- Not pregnant or breastfeeding and not planning to become pregnant or breastfeed
- Able to provide written informed consent
- May need to suspend aspirin or anti-inflammatory medication 7 days before participation if no known vascular disease
You will not qualify if you...
- Vulnerable populations are excluded
- Presence of chronic kidney disease (creatinine >2.5 mg/dL) or active cancers
- Pregnancy
- Anemia (hemoglobin <12 g/dL for men, <11 g/dL for women)
- Current smoking
- Use of chronic medications such as statins, anti-inflammatory drugs, ARBs, or ACE inhibitors
- Blood or plasma donation within the past 2 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo assessments including adipose tissue sampling and measurement of vascular and metabolic functions.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Mayo Clinic
Rochester, Minnesota, United States, 55901
Actively Recruiting
Research Team
S
Somers_CPL Lab
V
Virend Somers, MD., Ph.D
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here